Methods for improving cell therapy and tissue regeneration in patients with cardiovascular diseases by means of shockwaves

US9060915B2 · kind B2 · utility

Assignee

• Dornier MedTech Systems, GmbH · DE

Inventors

• Andreas Lutz · Bad Abbach, DE
• Harald Eizenhofer · Munich, DE
• Andreas M. Zeiher · Glückstadt, DE
• Stefanie Dimmeler · Frankfurt am Main, DE
• Christopher Heeschen · Frankfurt am Main, DE
• Alexandra Aicher · Frankfurt, DE

Key dates

• Filing date: Jun 20, 2008
• Grant date: Jun 23, 2015
• Expiry date: Jun 20, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61B2018/00392
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain.